Cargando…

Why did EFSA not reduce its ADI for aspartame or recommend its use should no longer be permitted?

On behalf of the European Food Safety Authority (EFSA), Kass and Lodi recently published a letter purporting to ‘refute’ our July 2019 analysis of EFSA’s December 2013 assessment of the risks of aspartame. We had previously claimed inter alia that the EFSA panel had evaluated studies that had indica...

Descripción completa

Detalles Bibliográficos
Autores principales: Millstone, Erik Paul, Dawson, Elisabeth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7654000/
https://www.ncbi.nlm.nih.gov/pubmed/33292494
http://dx.doi.org/10.1186/s13690-020-00489-w
_version_ 1783607990437281792
author Millstone, Erik Paul
Dawson, Elisabeth
author_facet Millstone, Erik Paul
Dawson, Elisabeth
author_sort Millstone, Erik Paul
collection PubMed
description On behalf of the European Food Safety Authority (EFSA), Kass and Lodi recently published a letter purporting to ‘refute’ our July 2019 analysis of EFSA’s December 2013 assessment of the risks of aspartame. We had previously claimed inter alia that the EFSA panel had evaluated studies that had indicated that aspartame might be harmful far more sceptically than those that had not indicated harm. We reported that EFSA had deemed every one of 73 studies suggesting harm to have been unreliable. Kass and Lodi provided a tabulation with figures that differed from ours in every detail. This commentary shows that, while Kass and Lodi provided a response to our analysis, they have not come close to refuting it. Our analysis provided detailed characterisations of each of the studies and how the panel interpreted them, but Kass and Lodi provide no corresponding information at all. Kass and Lodi claim that EFSA deemed 21 of 35 studies that had indicated possible harm to have been reliable. But if that is so, we now ask: why did the EFSA panel not recommend that aspartame should be banned, or at least tightly restricted? SUPPLEMENTARY INFORMATION: Supplementary information accompanies this paper at 10.1186/s13690-020-00489-w.
format Online
Article
Text
id pubmed-7654000
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-76540002020-11-10 Why did EFSA not reduce its ADI for aspartame or recommend its use should no longer be permitted? Millstone, Erik Paul Dawson, Elisabeth Arch Public Health Commentary On behalf of the European Food Safety Authority (EFSA), Kass and Lodi recently published a letter purporting to ‘refute’ our July 2019 analysis of EFSA’s December 2013 assessment of the risks of aspartame. We had previously claimed inter alia that the EFSA panel had evaluated studies that had indicated that aspartame might be harmful far more sceptically than those that had not indicated harm. We reported that EFSA had deemed every one of 73 studies suggesting harm to have been unreliable. Kass and Lodi provided a tabulation with figures that differed from ours in every detail. This commentary shows that, while Kass and Lodi provided a response to our analysis, they have not come close to refuting it. Our analysis provided detailed characterisations of each of the studies and how the panel interpreted them, but Kass and Lodi provide no corresponding information at all. Kass and Lodi claim that EFSA deemed 21 of 35 studies that had indicated possible harm to have been reliable. But if that is so, we now ask: why did the EFSA panel not recommend that aspartame should be banned, or at least tightly restricted? SUPPLEMENTARY INFORMATION: Supplementary information accompanies this paper at 10.1186/s13690-020-00489-w. BioMed Central 2020-11-09 /pmc/articles/PMC7654000/ /pubmed/33292494 http://dx.doi.org/10.1186/s13690-020-00489-w Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Commentary
Millstone, Erik Paul
Dawson, Elisabeth
Why did EFSA not reduce its ADI for aspartame or recommend its use should no longer be permitted?
title Why did EFSA not reduce its ADI for aspartame or recommend its use should no longer be permitted?
title_full Why did EFSA not reduce its ADI for aspartame or recommend its use should no longer be permitted?
title_fullStr Why did EFSA not reduce its ADI for aspartame or recommend its use should no longer be permitted?
title_full_unstemmed Why did EFSA not reduce its ADI for aspartame or recommend its use should no longer be permitted?
title_short Why did EFSA not reduce its ADI for aspartame or recommend its use should no longer be permitted?
title_sort why did efsa not reduce its adi for aspartame or recommend its use should no longer be permitted?
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7654000/
https://www.ncbi.nlm.nih.gov/pubmed/33292494
http://dx.doi.org/10.1186/s13690-020-00489-w
work_keys_str_mv AT millstoneerikpaul whydidefsanotreduceitsadiforaspartameorrecommenditsuseshouldnolongerbepermitted
AT dawsonelisabeth whydidefsanotreduceitsadiforaspartameorrecommenditsuseshouldnolongerbepermitted